| 臺大學術典藏 |
2022-09-19T03:16:34Z |
Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015
|
Wang C.-Y.; Huang H.-H.; Chen H.-M.; FEI-YUAN HSIAO; Ko B.-S. |
| 臺大學術典藏 |
2020-11-11T00:57:54Z |
Real-world Outcomes of Ultrasonography-guided Interventions in a Tertiary Hospital
|
Liao, Yk;Shyu, Sg;Chueh-Hung Wu; Liao, YK; Shyu, SG; CHUEH-HUNG WU |
| 臺大學術典藏 |
2021-01-21T02:52:29Z |
Real-world outcomes of ultrasonography-guided interventions in a tertiary hospital
|
Liao Y.-K.; SHAW-GANG SHYU; Wu C.-H. |
| 臺大學術典藏 |
2021-11-05T08:01:35Z |
Real-world outcomes of ultrasonography-guided interventions in a tertiary hospital
|
Liao Y.-K.; SHAW-GANG SHYU; Wu C.-H. |
| 臺大學術典藏 |
2021-05-27T02:50:07Z |
Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey)
|
Chuah Y.-Y.; Wu D.-C.; Chuah S.-K.; JYH-CHIN YANG; Lee T.-H.; Yeh H.-Z.; Chen C.-L.; Liu Y.-H.; Hsu P.-I. |
| 臺大學術典藏 |
2022-03-04T08:22:44Z |
Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey)
|
Chuah Y.-Y.; Wu D.-C.; Chuah S.-K.; JYH-CHIN YANG; Lee T.-H.; Yeh H.-Z.; Chen C.-L.; Liu Y.-H.; Hsu P.-I. |
| 國立臺灣海洋大學 |
2017 |
Real-World RESTful Service Composition: A Transformation-Annotation-Discovery Approach
|
Shang-Pin Ma;Hsuan-Ju Lin;Ci-Wei Lan;Wen-Tin Lee;Ming-Jen Hsu |
| 國立臺灣海洋大學 |
2017 |
Real-World RESTful Service Composition: A Transformation-Annotation-Discovery Approach
|
Shang-Pin Ma;Hsuan-Ju Lin;Ci-Wei Lan;Wen-Tin Lee;Ming-Jen Hsu |
| 國立成功大學 |
2021 |
Real-world results of immune checkpoint inhibitors from the taiwan national health insurance registration system
|
Hsieh, S.-T.;Ho, Ho H.-F.;Tai, H.-Y.;Chien, L.-C.;Chang, H.-R.;Chang, H.-P.;Huang, Y.-W.;Huang, J.-J.;Lien, H.-J.;Huang, L.-Y.;Lee, P.-C. |
| 國立成功大學 |
2021 |
Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System
|
Hsieh;S-T;Ho;H-F;Tai;H-Y;Chien;L-C;Chang;H-R;Chang;H-P;Huang;Y-W;Huang;J-J;Lien;H-J;Huang;L-Y;Lee;P-C |
| 臺大學術典藏 |
2020-03-05T06:05:26Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; LI-KAI TSAI; Liu Y.-B.; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2020-03-05T05:37:43Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.;Kuo C.-H.;Shin-Joe Yeh;Tsai L.-K.;Liu Y.-B.;Huang C.-F.;Tang S.-C.;Jeng J.-S.; Lin S.-Y.; Kuo C.-H.; SHIN-JOE YEH; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2020-03-02T12:10:28Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y; Kuo C.-H; Yeh S.-J; Tsai L.-K; Liu Y.-B; Huang C.-F; SUNG-CHUN TANG; Jeng J.-S. |
| 臺大學術典藏 |
2020-03-04T05:42:30Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y; Kuo C.-H; Yeh S.-J; Tsai L.-K; Liu Y.-B; Huang C.-F; SUNG-CHUN TANG; Jeng J.-S. |
| 臺大學術典藏 |
2020-11-03T11:07:55Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.;Kuo C.-H.;Yeh S.-J.;Tsai L.-K.;Liu Y.-B.;Huang C.-F.;Sung-Chun Tang;Jeng J.-S.; Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; SUNG-CHUN TANG; Jeng J.-S. |
| 臺大學術典藏 |
2021-07-08T08:19:41Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
SHIN YI LIN; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2020-11-03T12:37:38Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Jeng J.-S.; Tang S.-C.; Huang C.-F.; Liu Y.-B.; LI-KAI TSAI; Yeh S.-J.; Kuo C.-H.; Lin S.-Y.; Lin S.-Y.;Kuo C.-H.;Yeh S.-J.;Li-Kai Tsai;Liu Y.-B.;Huang C.-F.;Tang S.-C.;Jeng J.-S. |
| 臺大學術典藏 |
2021-06-04T06:23:03Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.;Ching-Hua Kuo;Yeh S.-J.;Tsai L.-K.;Liu Y.-B.;Huang C.-F.;Tang S.-C.;Jeng J.-S.; Lin S.-Y.; CHING-HUA KUO; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2021-07-05T07:06:07Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; CHIH-FEN HUANG; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2021-11-26T05:56:25Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; LI-KAI TSAI; Liu Y.-B.; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 臺大學術典藏 |
2021-12-22T03:53:44Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; Liu Y.-B.; Huang C.-F.; Tang S.-C.; JIANN-SHING JENG |
| 臺大學術典藏 |
2020-12-30T07:47:45Z |
Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
|
Lin S.-Y.; Kuo C.-H.; Yeh S.-J.; Tsai L.-K.; YEN BIN LIU; Huang C.-F.; Tang S.-C.; Jeng J.-S. |
| 國立成功大學 |
2020-07-14 |
Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience
|
Wu;Pei-Ying;Cheng;Ya-Min;Shen;Meng-Ru;Chen;Yi-Chun;Huang;Yu-Fang;Chou;Cheng-Yang |
| 國立成功大學 |
2020-07-14 |
Real-world Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-line or Relapse Therapy (ROBOT): 8-year Experience
|
黃于芳; Huang, Yu-Fang; Wu, Pei-Ying;Cheng, Ya-Min;Shen, Meng-Ru;Chen, Yi-Chun;Chou, Cheng-Yang |
| 國立成功大學 |
2024 |
Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries
|
Lee;C, -K.;Yoo;C;Hong;J, Y.;Park;S, J.;Kim;J, W.;Tai;D, W.M.;Kim;H;Korphaisarn;K;Tanasanvimon;S;Chen;S, -C.;Kim;J, W.;Kim;I;Kim;M;Choo;J;Oh;S, -B.;Chen;C, -T.;Bae;W, K.;Kim;H;Huh;S, J.;Yen;C, -J.;Park;S;Lee;D, K.;Chan;L, L.L.;Kang;B;Kang;M;Sundar;R;Choi;H, J.;Chan;S, L.;Chon;H, J.;Lee;M, -A. |
